Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visine Totality Multi-Symptom Relief
- Development stage
- Unknown
- Lead developer
- Kenvue
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Visine Totality Multi-Symptom Relief is an over-the-counter ophthalmic solution developed by Kenvue. It is a multi-ingredient formulation designed to provide comprehensive relief for various eye symptoms, including redness, burning, itching, and dryness. The product contains five active ingredients: tetrahydrozoline HCl, an alpha-adrenergic receptor agonist that acts as a vasoconstrictor to reduce ocular redness; zinc sulfate, which serves as an astringent to clear mucus and proteins from the ocular surface; and a triple-lubricant blend (glycerin, hypromellose, and polyethylene glycol 400) known as the Hydroblend moisturizer system. It is indicated for the temporary relief of eye discomfort and protection against further irritation for up to 10 hours.
- Brand names
- Visine Totality Multi-Symptom ReliefVisine Red Eye Total Comfort Multi-Symptom
- Other names
- Visine Totalityglycerin + hypromellose + polyethylene glycol 400 + tetrahydrozoline + zinc sulfate
02
Targets
ADRA1A (α1A)
Beyond the preview
Go deeper on Visine Totality Multi-Symptom Relief.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Visine Totality Multi-Symptom Relief.